Skip to main content

Table 2 Virological failure baseline clinical characteristics

From: Virological response to daclatasvir and asunaprevir combination therapy for chronic hepatitis C virus genotype 1b infection in dialysis patients: a prospective, multicenter study

Characteristics

Complete (n = 25)

Failure (n = 4)

P value

Age, years

64.9 ± 8.19

69.5 ± 2.69

0.182

Sex, male (n) [%]

21/25 (80.7)

2/4 (50.0)

0.180

Duration of hemodialysis (years)

16.1 ± 9.5

15.3 ± 10.4

0.393*

Previous treatment (n) [%]

 Naïve

19/25 (76.0)

1/4 (25.0)

0.076

 Relapse and non-viral response

6/25 (24.0)

3/4 (75.0)

 

Liver cirrhosis (n) [%]

6/25 (24.0)

3/4 (75.0)

0.076

Serum HCV-RNA levels (log10 IU/mL)

5.06 ± 0.99

5.88 ± 0.28

0.158*

 ≥5.0 log10 IU/mL (n) [%]

16/25 (64.0)

4/4 (100)

0.280

 ≥5.5 log10 IU/mL (n) [%]

9/25 (36)

4/4 (100)

0.030

NS5A inhibitor RAVs (n) [%]

2/25 (8)

0/4 (0)

1.000

  1. Data are expressed as median, number (%), or mean ± standard deviation
  2. *Mann-Whitney U test, Fisher’s exact test